USA |NASDAQ |USD
Report Date | Period Ending | EPS Forecast | Last Quarter's EPS | Last Year's EPS |
---|---|---|---|---|
Aug 8, 2022 | Jun 2022 | - | $5.08 | $2.47 |
Report Date | Period Ending | Revenue Forecast | Last Quarter’s Revenue | Last Year’s Revenue |
---|---|---|---|---|
Aug 8, 2022 | Jun 2022 | - | $320.27M | $153.62M |
Fulgent Genetics's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 2022.
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 3 | $6.49 | $6.32 | $6.66 |
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|
Period End | Up/Down 1M | 1M Trend | 2M Trend | 3M Trend |
---|---|---|---|---|
Dec 2022 | 1 / 0 | $6.27 | $6.27 | $6.04 |
Period End | # of Analysts | Revenue Forecast | Low Revenue Forecast | High Revenue Forecast |
---|
Period End | # of Analysts | EPS Forecast | Low EPS Forecast | High EPS Forecast |
---|---|---|---|---|
Dec 2022 | 3 | $587.87M | $578.20M | $601.00M |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Aug 8, 2022 | Jun 2022 | $1.18 | - | - |
May 3, 2022 | Mar 2022 | $3.86 | $5.08 | 31.61% |
Feb 23, 2022 | Dec 2021 | $2.61 | $3.34 | 27.97% |
Nov 9, 2021 | Sep 2021 | $3.25 | $4.05 | 24.62% |
Aug 9, 2021 | Jun 2021 | $2.67 | $2.47 | -7.58% |
May 6, 2021 | Mar 2021 | $5.70 | $6.52 | 14.39% |
Mar 4, 2021 | Dec 2020 | $4.05 | $6.20 | 52.96% |
Nov 9, 2020 | Sep 2020 | $0.55 | $2.08 | 278.18% |
Aug 4, 2020 | Jun 2020 | $0.01 | $0.17 | 1600.00% |
May 4, 2020 | Mar 2020 | $0.02 | $-0.03 | -242.86% |
Mar 10, 2020 | Dec 2019 | $0.02 | $0.04 | 105.13% |
Nov 4, 2019 | Sep 2019 | $0.03 | $0.14 | 366.67% |
Aug 5, 2019 | Jun 2019 | $-0.00 | $0.06 | 3100.00% |
May 7, 2019 | Mar 2019 | $-0.01 | $-0.06 | -361.54% |
Feb 28, 2019 | Dec 2018 | $-0.02 | $-0.01 | 33.33% |
Nov 6, 2018 | Sep 2018 | $-0.03 | $-0.03 | -32.00% |
Aug 6, 2018 | Jun 2018 | $-0.03 | $-0.01 | 66.67% |
May 7, 2018 | Mar 2018 | $-0.04 | $-0.06 | -71.43% |
Feb 28, 2018 | Dec 2017 | $-0.02 | $-0.06 | -268.10% |
Nov 6, 2017 | Sep 2017 | $0.02 | $-0.02 | -183.33% |
Aug 7, 2017 | Jun 2017 | $0.02 | $0.02 | 25.00% |
May 8, 2017 | Mar 2017 | $0.06 | $0.03 | -45.45% |
Feb 27, 2017 | Dec 2016 | $0.07 | $0.06 | -12.79% |
Nov 3, 2016 | Sep 2016 | $0.09 | $0.11 | 16.40% |
Report Date | Period Ending | Forecast EPS | Actual EPS | Surprise |
---|---|---|---|---|
Feb 23, 2022 | Dec 2021 | $15.68 | $16.38 | 4.45% |
Mar 4, 2021 | Dec 2020 | $6.28 | $8.42 | 34.08% |
Mar 10, 2020 | Dec 2019 | $0.17 | $0.18 | 5.88% |
Feb 28, 2019 | Dec 2018 | $-0.10 | $-0.11 | - |
Feb 28, 2018 | Dec 2017 | $0.01 | $-0.03 | - |
Feb 27, 2017 | Dec 2016 | - | $0.17 | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Aug 8, 2022 | Jun 2022 | - | - | - |
May 3, 2022 | Mar 2022 | $197.55M | $320.27M | 1.62% |
Feb 23, 2022 | Dec 2021 | $191.10M | $251.67M | 1.32% |
Nov 9, 2021 | Sep 2021 | $131.96M | $227.87M | 1.73% |
Aug 9, 2021 | Jun 2021 | $153.62M | $153.62M | 1.00% |
May 6, 2021 | Mar 2021 | $321.51M | $359.43M | 1.12% |
Mar 4, 2021 | Dec 2020 | $199.44M | $294.98M | 1.48% |
Nov 9, 2020 | Sep 2020 | $48.46M | $101.72M | 2.10% |
Aug 4, 2020 | Jun 2020 | $10.02M | $17.27M | 1.72% |
May 4, 2020 | Mar 2020 | $7.74M | $7.75M | 1.00% |
Mar 10, 2020 | Dec 2019 | $8.51M | $8.39M | 0.99% |
Nov 4, 2019 | Sep 2019 | $8.45M | $10.35M | 1.22% |
Aug 5, 2019 | Jun 2019 | $6.42M | $8.42M | 1.31% |
May 7, 2019 | Mar 2019 | $5.60M | $5.37M | 0.96% |
Feb 28, 2019 | Dec 2018 | $5.84M | $5.67M | 0.97% |
Nov 6, 2018 | Sep 2018 | $5.38M | $5.62M | 1.05% |
Aug 6, 2018 | Jun 2018 | $4.93M | $5.40M | 1.10% |
May 7, 2018 | Mar 2018 | $5.12M | $4.65M | 0.91% |
Feb 28, 2018 | Dec 2017 | $5.12M | $4.28M | 0.84% |
Nov 6, 2017 | Sep 2017 | $5.61M | $4.50M | 0.80% |
Aug 7, 2017 | Jun 2017 | $4.81M | $4.64M | 0.96% |
May 8, 2017 | Mar 2017 | - | $5.31M | - |
Feb 27, 2017 | Dec 2016 | - | $5.85M | - |
Nov 3, 2016 | Sep 2016 | - | $5.01M | - |
Report Date | Period Ending | Forecast Revenue | Actual Revenue | Surprise |
---|---|---|---|---|
Feb 23, 2022 | Dec 2021 | $933.03M | $992.58M | 6.38% |
Mar 4, 2021 | Dec 2020 | $326.20M | $421.71M | 29.28% |
Mar 10, 2020 | Dec 2019 | $32.67M | $32.53M | -0.43% |
Feb 28, 2019 | Dec 2018 | $21.52M | $21.35M | -0.79% |
Feb 28, 2018 | Dec 2017 | $19.58M | $18.73M | -4.34% |
Feb 27, 2017 | Dec 2016 | - | $18.28M | - |
FLGT's next earnings date is Monday, Aug 8, 2022 for the fiscal quarter ending Jun 30, 2022.
The average EPS estimation for Fulgent Genetics's next quarterly earnings is $1.18.
Fulgent Genetics's previous earnings date was May 3, 2022 for its fiscal quarter ended Mar 31, 2022.
FLGT's earnings per share (EPS) was $5.08, beating the consensus analysts forecast of $3.86 by 31.61%.
The EPS was higher than the previous fiscal quarter (Dec 2021) by 52.10%, and lower than the same period a year before (Mar 2021) by -22.09%.
Revenues were $320.27M, up by 27.26% from the previous quarter , and down by -10.90% from the same period last year.
The company reported a net income of $153.98M, 47.58% higher than the previous quarter, and lower by -23.28% than the same period a year before.
Fulgent Genetics's previous annual earnings date was Feb 23, 2022 for its fiscal year ended Dec 31, 2021.
FLGT's earnings per share (EPS) was $16.38, beating the consensus analysts forecast of $15.68 by 4.45% , and higher than the previous year's EPS (Dec 2020) by 94.51%.
Revenues were $992.58M, better than the forecast of $933.03M by 6.38%, and up by 135.37% from previous year's revenue.
The company reported a net income of $507.36M, 136.74% higher than the previous year.
Fulgent Genetics reported a free cash flow of $514.73M for its fiscal year, compared to $104.12M a year ago.
The company ended the fiscal year with $21.28M in total debt, an increase of 34.25% compared to the previous year.
Get a weekly snapshot of one new investment idea from stock exchanges worldwide.